GlassScriptPhysician profile
Kaywan D Gamadia
NPI 1063699833
$458,435.36
in general payments reported to CMS, 2019-2025
13 companies · $29K in 2025
The $29K reported for 2025 was more than what 92% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76K · 2020: $68K · 2021: $39K · 2022: $69K · 2023: $88K · 2024: $90K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $207K · Food and Beverage: $295 · Education: $60.00 · Gift: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $206,722.96 |
| Food and Beverage | $294.59 |
| Education | $60.00 |
| Gift | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genesys Orthopedics Systems, L.L.C. | $449,915.67 | 2019-2025 | Sacroiliac Joint Fusion System |
| Corelink, LLC | $7,377.28 | 2019-2022 | |
| Medtronic USA, INC. | $523.89 | 2019-2020 | |
| Medtronic, INC. | $271.42 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Sanara Medtech INC. | $132.70 | 2020 | |
| Csl Behring | $60.00 | 2024 | Kcentra |
| Portola Pharmaceuticals, LLC | $48.34 | 2019 | |
| Globus Medical, INC. | $23.17 | 2025 | Senza |
| Convatec INC. | $22.13 | 2019 | |
| Zimmer Biomet Holdings, INC. | $19.32 | 2019 | |
| Boston Scientific Corporation | $14.58 | 2019 | |
| Celgene Corporation | $14.35 | 2019 | |
| Abbott Laboratories | $12.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaywan Gamadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.